Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker LRMR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Blue Owl Capital Holdings LP | 10.74M | 10.0% | SCHEDULE 13G/A ↗ |
| Apr 30, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Israel A. Englander | 3.63M | 3.5% | SCHEDULE 13G/A ↗ |
| Apr 30, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Millennium Group Management LLC | 3.63M | 3.5% | SCHEDULE 13G/A ↗ |
| Apr 30, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Millennium Management LLC | 3.63M | 3.5% | SCHEDULE 13G/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | James E. Flynn | 35.67M | 34.4% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Management Company, L.P. | 35.67M | 34.4% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt, L.P. | 6.21M | 6.0% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt IV, L.P. | 10.62M | 10.3% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt HIF, L.P. | 8.15M | 7.9% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt III, L.P. | 10.62M | 10.3% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Partners, L.P. | 6.21M | 6.0% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Private Design Fund IV, L.P. | 10.62M | 10.3% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Healthcare Innovations Fund, L.P. | 8.15M | 7.9% | SCHEDULE 13D/A ↗ |
| Mar 2, 2026 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Private Design Fund III, L.P. | 10.62M | 10.3% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Rajeev Shah | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Peter Kolchinsky | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | RA Capital Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Blue Owl Capital Holdings LP | 8.46M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 6, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Israel A. Englander | 4.97M | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Millennium Group Management LLC | 4.97M | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Millennium Management LLC | 4.97M | 5.8% | SCHEDULE 13G/A ↗ |
| Aug 29, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | James Silverman | 4.11M | 4.8% | SCHEDULE 13G ↗ |
| Aug 29, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Opaleye, L.P. | 4.11M | 4.8% | SCHEDULE 13G ↗ |
| Aug 29, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Opaleye Management, Inc. | 4.11M | 4.8% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Janus Henderson Group PLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | James E. Flynn | 30.67M | 35.8% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Management Company, L.P. | 30.67M | 35.8% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt, L.P. | 4.21M | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt IV, L.P. | 9.54M | 11.1% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt HIF, L.P. | 7.32M | 8.6% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Mgmt III, L.P. | 9.54M | 11.1% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Partners, L.P. | 4.21M | 4.9% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Private Design Fund IV, L.P. | 9.54M | 11.1% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Healthcare Innovations Fund, L.P. | 7.32M | 8.6% | SCHEDULE 13D/A ↗ |
| Jul 31, 2025 | SCHEDULE 13D/A (amended) | LRMR Larimar Therapeutics, Inc. | Deerfield Private Design Fund III, L.P. | 9.54M | 11.1% | SCHEDULE 13D/A ↗ |
| Jun 17, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Israel A. Englander | 3.56M | 5.6% | SCHEDULE 13G ↗ |
| Jun 17, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Millennium Group Management LLC | 3.56M | 5.6% | SCHEDULE 13G ↗ |
| Jun 17, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Millennium Management LLC | 3.56M | 5.6% | SCHEDULE 13G ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 3.36M | 9.1% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Janus Henderson Group PLC | 5.57M | 8.7% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Goldman Sachs & Co. LLC | 2.60M | 4.1% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | The Goldman Sachs Group, Inc. | 2.60M | 4.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | BlackRock, Inc. | 3.08M | 4.8% | SCHEDULE 13G/A ↗ |
| Apr 16, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | James Silverman | 3.95M | 6.2% | SCHEDULE 13G ↗ |
| Apr 16, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Opaleye, L.P. | 3.95M | 6.2% | SCHEDULE 13G ↗ |
| Apr 16, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | Opaleye Management, Inc. | 3.95M | 6.2% | SCHEDULE 13G ↗ |
| Feb 4, 2025 | SCHEDULE 13G | LRMR Larimar Therapeutics, Inc. | BlackRock, Inc. | 3.27M | 5.1% | SCHEDULE 13G ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 5.45M | 8.5% | SCHEDULE 13G/A ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | LRMR Larimar Therapeutics, Inc. | Janus Henderson Group PLC | 6.44M | 10.1% | SCHEDULE 13G/A ↗ |
50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances